
LFST Stock Forecast & Price Target
LFST Analyst Ratings
Bulls say
LifeStance Health Gr is well positioned for sustained growth because its core outpatient mental health platform still has significant share gains ahead, with less than 5% share in most markets and presence in only about half of the 150 largest U.S. geographies. The company’s recent quarter showed strong fundamentals, including revenue of $455.9 million, 25.3% growth, adjusted EBITDA of $68.4 million, and a roughly 15% margin, supported by flat-to-up clinician productivity, 17% visit growth, and 7% higher revenue per visit. Its specialty care opportunity adds further upside through higher-acuity treatments like Spravato and TMS, while strong outcomes, internal patient referrals, and disciplined cost management support margin expansion and a durable earnings trajectory.
Bears say
LifeStance Health Gr is pressured by heavy reimbursement dependence, as UnitedHealthcare and Elevance Health together represented 29% of FY25 revenue, so any rate cuts, network exclusions, or contract losses could quickly impair results. Its outlook is further constrained by intense competition for clinicians, which can raise labor costs and limit growth if retention weakens, while patient volumes remain vulnerable to economic stress and insurance coverage losses. Although Specialty Care and Spravato offer growth potential, adoption is slowed by clinician training, qualification hurdles, and reimbursement economics that already make some geographies unviable, reducing near-term operating leverage.
This aggregate rating is based on analysts' research of LifeStance Health Group and is not a guaranteed prediction by Public.com or investment advice.
LFST Analyst Forecast & Price Prediction
Start investing in LFST
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About LifeStance Health Group (LFST) Forecast
LFST Analyst Forecast & Price Prediction
Start investing in LFST
Order type
Buy in
Order amount
Est. shares
0 shares